20260706-西牛证券-真健康医疗-B-02697.HK-Leading_puncture_robot_manufacturer_+_organ_perfusion_platform,_opening_up_a_new_frontier_in_minimally_invasive_intervention_and_organrepair_in_China_40页_1mb

TrueHealth (02697.HK) Summary

Core Content

TrueHealth (02697.HK) is a leading Chinese medical equipment company specializing in percutaneous puncture and ablation surgical robots, as well as organ perfusion and assessment systems. The company is positioned as the first in China to offer a comprehensive product portfolio covering all three robotic technology pathways: puncture, ablation, and organ preservation. This diversified approach enables TrueHealth to address a wide range of applications in minimally invasive oncology and organ transplantation, aligning with the growing demand for advanced medical technologies in China.

Main Products and Technology

TrueHealth offers a range of surgical robots and organ perfusion systems, including:

• Percutaneous Puncture Surgical Robots:

  • TH-S1, TH-S, TH-S Pro, TH-SA: All have NMPA Class III registration for lung and abdominal procedures.
  • TH-P series: Miniaturized devices suitable for county-level hospitals and specialized biopsy settings.

• Ablation Surgical Robots:

  • TH-X MW and TH-X HMW: Approved for liver tumour ablation, with TH-X MW further approved for lung tumour treatment in April 2026.
  • MW150: A standalone microwave ablation device.
  • TH-X Cryo: A cryoablation robot under development, with registration expected in H2 2027.

• Organ Perfusion Systems:

  • TH-LS KJ300: Normothermic kidney preservation and assessment system, with clinical trial planned for H1 2031.
  • TH-LS LU100: Normothermic multi-organ preservation and assessment system, with clinical trial planned for H1 2027.

Key Advantages

• High precision: Utilizes 3D image reconstruction, AI lesion segmentation, and dynamic robotic arm navigation to enhance accuracy and reduce complications.
• Minimally invasive: Offers precision biopsy, targeted ablation, and radioactive particle implantation with reduced surgical complexity and improved patient outcomes.
• Comprehensive product ladder: Products are tailored for different hospital tiers, from national medical centers to county-level hospitals.
• Recurring revenue model: Shifts from one-off equipment sales to a high-margin, high-repeat-purchase model through consumables and maintenance services.

Commercialization and Market Strategy

• Distributor network: Active in 23 key provinces in China, with a focus on sales and leasing models.
• Direct tendering: Has developed direct procurement capabilities, with the first direct sale achieved in April 2026.
• Pricing and reimbursement: The Group benefits from expanding surgical robot pricing and reimbursement policies, which are expected to drive hospital adoption.
• Global expansion: Submitted a CE marking application in January 2026, aiming to enter European and Lusophone markets (e.g., Brazil) through Macau as a regional hub.

Financial Performance and Valuation

• Earnings growth: Driven by rising installations and consumables uptake, with recurring revenue streams from consumables and services.
• Revenue forecast:
  • 2025: RMB 12.2 million
  • 2026: RMB 58.3 million
  • 2027: RMB 175.2 million
  • 2028: RMB 263.9 million
• Gross margin:
  • 2025: 76.3%
  • 2026: 81.3%
  • 2027: 79.2%
  • 2028: 79.8%
• Target price: HK$ 448.80, with a "Buy" rating, reflecting strong growth potential and a favorable risk-reward profile.

Investment Thesis

TrueHealth is well-positioned to capitalize on the minimally invasive intervention market in China, driven by:

• A comprehensive product portfolio covering puncture, ablation, and organ preservation.
• A demand-driven commercialization model that supports device + consumables revenue.
• Significant policy-driven opportunities, particularly in the organ preservation space, which addresses China's severe organ-supply shortfall.
• A strong R&D foundation with 71 dedicated researchers and collaborations with top-tier institutions such as Tsinghua University, Tianjin University, and Shanghai Jiao Tong University.

Key Risks

• Commercialization delays: Slower hospital procurement or installation may impact revenue growth.
• Reimbursement policy delays: Fee code rollout could affect hospital purchasing willingness.
• Intensifying competition: From domestic and international peers, including Edge Medical.
• R&D delays: Especially for the organ preservation system, which is critical for medium-to-long-term growth.

R&D and Collaborations

• R&D team: 71 members.
• Collaborations:
  • With Tianjin University, Beijing Institute of Technology, General Hospital of the People's Liberation Army, and Guangzhou Medical University for clinical demonstration bases.
  • With Macao Polytechnic University for navigation system R&D.
  • With University of Macau and Shanghai Jiao Tong University for AI robotics.
  • With Tsinghua University for 3D medical image registration and fusion.

Production and Capacity

• Zhuhai factory: 3,682m² with two production lines:
  • One for mass production (50 units annually).
  • One for validation, optimization, and quality control.
• Cleanroom: For medical consumables.
• Future plans:
  • Expand to 10,000m².
  • Replace optical navigation systems with domestically developed solutions within three years.
  • Achieve full in-house autonomy for robotic arms within five years.

Company Background

• Founded in 2018, TrueHealth relocated to the Hengqin Guangdong-Macao In-depth Cooperation Zone in 2023 with support from the Hengqin Government and the Central Committee of the Communist Party of China.
• Officially listed on the Hong Kong Stock Exchange in June 2026 under code 02697.HK, with an issue price of HK$ 126.20 per share.

Conclusion

TrueHealth is a high-growth medical robotics company with a comprehensive product portfolio and a robust commercialization strategy. Its focus on puncture, ablation, and organ preservation aligns with key clinical needs in China, while its expanding distributor network and direct tendering capabilities are expected to drive revenue and market penetration. The organ perfusion platform presents meaningful long-term upside, particularly in addressing organ supply challenges. Despite competitive pressures and regulatory uncertainties, the company's innovative technology, strong R&D, and strategic expansion make it an attractive investment in the minimally invasive medical device sector.